Here are the 10-K annual reports from Krystal Biotech, Inc. (KRYS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow KRYS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KRYS filings page.
Krystal Biotech, Inc. provides an annual overview of its commercial-stage gene therapy business, centered on its HSV‑1-based redosable platform. The company’s first product, VYJUVEK, is approved in the United States, European Union, and Japan for dystrophic epidermolysis bullosa and has generated $730.3 million in net product revenue since launch.
Krystal is expanding VYJUVEK globally, with launches in Germany, France and Japan and additional distribution agreements across Europe and the Middle East. It reports broad clinical activity across respiratory, ophthalmology, dermatology, oncology and aesthetics programs, including inhaled KB407 for cystic fibrosis, KB408 for alpha‑1 antitrypsin deficiency, ocular candidates KB803 and KB801, dermatology program KB111, oncology asset KB707 for lung cancer, and aesthetic candidates KB304 and KB301.
The company emphasizes in‑house commercial‑scale CGMP manufacturing through its ANCORIS and ASTRA facilities, which support VYJUVEK supply and its broader pipeline. Krystal also highlights a growing global intellectual property estate around its HSV‑1 vector platform, commercial product and pipeline candidates.